Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-0789
    Keywords: Nicotiana tabacum L. ; Nicotiana rustica L. ; Zea mays L. ; Cadmium ; Bioavailability ; Phytotoxicity ; Pollution ; Translocation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Geosciences , Agriculture, Forestry, Horticulture, Fishery, Domestic Science, Nutrition
    Notes: Summary Mature (flowering) tobacco (Nicotiana tabacum cv. PBD6, Nicotiana rustica cv. Brasilia) and maize (Zea mays cv. INRA 260) plants were grown in an acid sandy-clay soil, enriched to 5.4 mg Cd kg−1 dry weight soil with cadmium nitrate. The plants were grown in containers in the open air. No visible symptoms of Cd toxicity developed on plant shoots over the 2-month growing period. Dry-matter yields showed that while the Nicotiana spp. were unaffected by the Cd application the yield of Z. mays decreased by 21%. Cd accumulation and distribution in leaves, stems and roots were examined. In the control treatment (0.44 mg Cd kg−1 dry weight soil), plant Cd levels ranged from 0.4 to 6.8 mg kg−1 dry weight depending on plant species and plant parts. Soil Cd enrichment invariably increased the Cd concentrations in plant parts, which varied from 10.1 to 164 mg kg−1 dry weight. The maximum Cd concentrations occurred in the leaves of N. tabacum. In N. rustica 75% of the total Cd taken up by the plant was transported to the leaves, and 81% for N. tabacum irrespective of the Cd level in the soil. In contrast, the Cd concentrations in maize roots were almost five times higher than those in the leaves. More than 50% of the total Cd taken up by maize was retained in the roots at both soil Cd levels. The Cd level in N. tabacum leaves was 1.5 and 2 times higher at the low and high Cd soil level, respectively, than that in N. rustica leaves, but no significant difference was found in root Cd concentrations between the two Nicotiana spp. Cd bioavailability was calculated as the ratio of the Cd level in the control plants to that in the soil or as the ratio of the additional Cd taken up from cadmium nitrate to the amount of Cd applied. The results showed that the plant species used can be ranked in a decreasing order as follows: N. tabacum 〉 N. rustica 〉 Z. mays.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0584
    Keywords: Key words Allogeneic bone marrow transplantation ; Autologous bone marrow transplantation ; Granulocyte colony-stimulating factor (G-CSF) ; Hematopoietic recovery
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  The positive role of G-CSF in hastening the myeloid recovery of patients undergoing allogeneic bone marrow transplantation (ALLO-BMT) or autologous bone marrow transplantation (ABMT) has recently been established. Considerable knowledge about adequate doses and route of administration has been accumulated in the past few years. Nonetheless, the optimal time to start growth-factor administration remains undetermined. We have performed a stratified study according to the source of hematopoietic progenitors (ALLO-BMT or ABMT), underlying disease and its stage, and acute graft-versus-host disease (GVHD) prophylaxis regimen and randomized patients in two arms: group A, which started G-CSF on day 0 (36 patients), and group B, which started on day +7 post-BMT (39 patients). The same dose (5 μg/kg/day) and route of administration were employed in both groups. We found no significant differences in the time to reach an absolute neutrophil count (ANC) of 0.1, 0.5, and 1×109/l and 50×109 platelets/l (medians: 10 and 11, 14.5 and 14, 17 and 16, 23 and 24 days, respectively, in groups A and B). We did not find differences in the days of fever or days on antibiotic treatment with less than 1×109/l ANC, rate of bacteriemia, or days of hospitalization in both groups. In contrast, a considerable saving of G-CSF in B group was found (mean days of infusion in group A, 18, versus 11 in group B) (p〈0.0001). This is equivalent to a saving of 1120 $US per patient. Therefore, early use of G-CSF after BMT is useless and more expensive and provides no advantage over delayed administration.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0584
    Keywords: Allogeneic bone marrow transplantation ; Autologous bone marrow transplantation ; Granulocyte colony-stimulating factor (G-CSF) ; Hematopoietic recovery
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The positive role of G-CSF in hastening the myeloid recovery of patients undergoing allogeneic bone marrow transplantation (ALLO-BMT) or autologous bone marrow transplantation (ABMT) has recently been established. Considerable knowledge about adequate doses and route of administration has been accumulated in the past few years. Nonetheless, the optimal time to start growth-factor administration remains undetermined. We have performed a stratified study according to the source of hematopoietic progenitors (ALLO-BMT or ABMT), underlying disease and its stage, and acute graft-versus-host disease (GVHD) prophylaxis regimen and randomized patients in two arms: group A, which started G-CSF on day 0 (36 patients), and group B, which started on day +7 post-BMT (39 patients). The same dose (5 Μg/kg/day) and route of administration were employed in both groups. We found no significant differences in the time to reach an absolute neutrophil count (ANC) of 0.1, 0.5, and 1×109/l and 50×109 platelets/l (medians: 10 and 11, 14.5 and 14, 17 and 16, 23 and 24 days, respectively, in groups A and B). We did not find differences in the days of fever or days on antibiotic treatment with less than 1×109/l ANC, rate of bacteriemia, or days of hospitalization in both groups. In contrast, a considerable saving of GCSF in B group was found (mean days of infusion in group A, 18, versus 11 in group B) (p〈0.0001). This is equivalent to a saving of 1120 $US per patient. Therefore, early use of G-CSF after BMT is useless and more expensive and provides no advantage over delayed administration.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...